12:00 AM
Jul 17, 2000
 |  BC Week In Review  |  Company News  |  Deals

Avigen, Stratagene Holding deal

Stratagene obtained worldwide exclusive rights from AVGN to sell kits for making recombinant adeno-associated virus (AAV) vectors. AVGN will...

Read the full 75 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >